These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 36039183)

  • 1. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
    Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
    Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
    Nicholls SJ; Schwartz GG; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Ray KK;
    Cardiovasc Diabetol; 2021 Jan; 20(1):13. PubMed ID: 33413345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
    Kalantar-Zadeh K; Schwartz GG; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kulikowski E; Lebioda K; Toth PP; Wong N; Sweeney M; Ray KK;
    Clin J Am Soc Nephrol; 2021 May; 16(5):705-716. PubMed ID: 33906908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
    Haarhaus M; Ray KK; Nicholls SJ; Schwartz GG; Kulikowski E; Johansson JO; Sweeney M; Halliday C; Lebioda K; Wong N; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
    Atherosclerosis; 2019 Nov; 290():59-65. PubMed ID: 31568963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Ray KK; Nicholls SJ; Ginsberg HD; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Cummings JL; Sweeney M; Schwartz GG
    Am Heart J; 2019 Nov; 217():72-83. PubMed ID: 31520897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
    Schwartz GG; Nicholls SJ; Toth PP; Sweeney M; Halliday C; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Ginsberg HN; Ray KK
    Cardiovasc Diabetol; 2021 Jun; 20(1):125. PubMed ID: 34158057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
    Ray KK; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Schwartz GG;
    JAMA; 2020 Apr; 323(16):1565-1573. PubMed ID: 32219359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
    Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
    Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
    Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
    Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
    Diabetes Obes Metab; 2023 Mar; 25(3):758-766. PubMed ID: 36394384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
    Brandts J; Ray KK
    Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the longitudinal trajectory of urinary albumin/creatinine ratio in diabetic patients with adverse cardiac event risk: a retrospective cohort study.
    Li H; Ren Y; Duan Y; Li P; Bian Y
    Front Endocrinol (Lausanne); 2024; 15():1355149. PubMed ID: 38745945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
    Oulhaj A; Aziz F; Suliman A; Eller K; Bentoumi R; Buse JB; Al Mahmeed W; von Lewinski D; Coleman RL; Holman RR; Sourij H
    Diabetes Obes Metab; 2024 Oct; 26(10):4602-4612. PubMed ID: 39086032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of hepatic steatosis and fibrosis with heart failure and mortality.
    Park J; Kim G; Kim H; Lee J; Lee YB; Jin SM; Hur KY; Kim JH
    Cardiovasc Diabetol; 2021 Sep; 20(1):197. PubMed ID: 34583706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B; Ghosal S
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
    Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
    Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.